Drug Trial Radar · NCT05605535
Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
88
Planned (sponsor's estimate)
Start
Feb 7, 2023
Primary completion
May 15, 2027
Study completion Sep 15, 2027
Sponsor
- Lead sponsor
- CanariaBio Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Raptim Research
- First posted
- Nov 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A clinical study to compare the efficacy and safety of five administrations of oregovomab versus placebo, infused in schedule dependent sequence with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of patients with newly diagnosed advanced ovarian cancer who are planned to receive neoadjuvant treatment followed by interval debulking surgery (IDS) and adjuvant treatment.
Conditions
- Ovarian Neoplasm Epithelial
- Ovarian Cancer
- Fallopian Tube Neoplasms
- Peritoneal Carcinoma
- Ovarian Serous Adenocarcinoma
Interventions
OregovomabBiological
2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
PaclitaxelDrug
175 mg/m\^2, every 3 weeks
CarboplatinDrug
AUC 5 or 6 IV Day 1 x 6 cycles (every 21 days)
PlaceboBiological
2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) Rate at 12 monthsTime frame: At 12 months
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Omega Hospitals
Visakhapatnam, Andhra Pradesh, India
King George Hospital
Visakhapatnam, Andhra Pradesh, India
Himalaya Cancer Hospital and Research Institute
Vadodara, Gujarat, India
Kailash Cancer Hospital and Research Centre
Vadodara, Gujarat, India
KLES Dr. Prabhakar Kore Hospital and Medical Research Centre
Belagavi, Karnataka, India
Amrita Institute of Medical Sciences
Kochi, Kerala, India
Regional Cancer Centre, Medical College
Trivandrum, Kerala, India
JIPMER
Puducherry, Puducherry, India
Sri Ram Cancer Hospital
Jaipur, Rajasthan, India
Saveetha Medical College and Hospitals
Chennai, Tamil Nadu, India
Sri Ramchandra Medical Centre
Chennai, Tamil Nadu, India
MNJ Cancer Hospital
Hyderabad, Telangana, India
King Georges Medical University
Lucknow, Uttar Pradesh, India
Institute of Medical Sciences, BHU
Varanasi, Uttar Pradesh, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.